title: Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.
abstract: The mammalian brain dynamically activates or silences gene programs in response to environmental input and developmental cues. This neuroplasticity is controlled by signaling pathways that modify the activity, localization, and/or expression of transcriptional-regulatory enzymes in combination with alterations in chromatin structure in the nucleus. Consistent with this key neurobiological role, disruptions in the fine-tuning of epigenetic and transcriptional regulation have emerged as a recurrent theme in studies of the genetics of neurodevelopmental and neuropsychiatric disorders. Furthermore, environmental factors have been implicated in the increased risk of heterogeneous, multifactorial, neuropsychiatric disorders via epigenetic mechanisms. Aberrant epigenetic regulation of gene expression thus provides an attractive unifying model for understanding the complex risk architecture of mental illness. Here, we review emerging genetic evidence implicating dysregulation of histone lysine methylation in neuropsychiatric disease and outline advancements in small-molecule probes targeting this chromatin modification. The emerging field of neuroepigenetic research is poised to provide insight into the biochemical basis of genetic risk for diverse neuropsychiatric disorders and to develop the highly selective chemical tools and imaging agents necessary to dissect dynamic transcriptional-regulatory mechanisms in the nervous system. On the basis of these findings, continued advances may lead to the validation of novel, disease-modifying therapeutic targets for a range of disorders with aberrant chromatin-mediated neuroplasticity.
authors.affiliation: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA.|Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.|Departments of Neurology & Psychiatry, Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
authors.forename: Emily L
authors.initials: EL
authors.lastname: Ricq
authors.affiliation: Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Hooker
authors.affiliation: Departments of Neurology & Psychiatry, Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Haggarty
mesh_terms: D000818:Animals; D055808:Drug Discovery; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000502:physiology*; D056466:Histone Demethylases / Q000187:drug effects / Q000378:metabolism*; D011495:Histone-Lysine N-Methyltransferase / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000201:enzymology*; D009422:Nervous System Diseases / Q000188:drug therapy / Q000201:enzymology*; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology*
chemical_list: D056466:Histone Demethylases; D011495:Histone-Lysine N-Methyltransferase
keywords: chromatin; drug discovery; epigenetics; histone lysine methylation; neuropsychiatric disorder